An FCM analysis of BM and PB samples from patients undergoing daratumumab treatment revealed that the response to daratumumab monotherapy is, in part, dependent on the baseline CD38 expression levels in tumor cells, and that treatment leads to a significant reduction in CD38 expression independent of treatment response, indicating that it is not the sole mechanism of daratumumab resistance. Here, CD38 is linked to neoplasm.